Pharma News - Chemdiv

NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial

NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase Ib/IIa stud...

Merck KGaA is now the fourth Big Pharma to sign on to a collaboration with C4 Therapeutics.

Apparently, C4 Therapeutics' protein degradation tech brings all the Mercks to the yard. The Massachusetts biotech has signed on Merck KGaA in a $740 million biobucks partnership to find two...

First UK cancer patients receive Moderna’s experimental mRNA therapy

In partnership between Imperial College London (ICL) and Imperial College Healthcare NHS Trust (ICHNT), the international Mobilize trial has issued first doses of Moderna’s experimental mRNA the...

Zinpentraxin alfa comparable to placebo in idiopathic pulmonary fibrosis

Among patients with idiopathic pulmonary fibrosis, lung function decline was comparable between 52-week zinpentraxin alfa treatment and placebo, according to results published in American Journal ...

FDA doubles down on patient engagement to support rare disease research

For Rare Disease Day, several panels organised by the FDA discussed the importance overcoming accessibility barriers during drug development.

Pfizer’s RSV vaccine Abrysvo shown to maintain strong efficacy in older adults

RSV infections account for up to 160,000 hospitalisations among older adults each year in the US.

Survodutide Improves Liver Disease Progression in More than 80% of Patients with MASH

After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.

Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal

On February 26, Neomorph announced that it has inked a $1.46 billion collaboration and licensing agreement with Novo Nordisk to embark on the discovery, development, and commercialization of molec...

FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease.

GSK, pushing back UTI filing by a year, shows antibiotic's gonorrhea potential in phase 3

GSK may have pushed back plans to secure approval for gepotidacin as the first new urinary tract infection (UTI) treatment in 20 years, but fresh phase 3 results have lined up the antibiotic for a...

Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.

Jacobio Pharma, a clinical-stage oncology company drugging the undruggable targets, announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C ac...

Cleveland Clinic researchers uncover how virus causes cancer, point to potential treatment

Cleveland Clinic researchers have discovered a key mechanism used by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer.

Pharma News, 2024